Sio Gene Therapies Inc.
DelistedCIK 1636050fmd_19VAY00TVNBZVVACS2NSTA32VDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2014 to Dec 31, 2022, 32 periods
Latest annual · FY2022
Millions- Operating income
- (72)
- Net income
- (72)
Latest quarter · Q3 FY2023
Millions- Operating income
- (4)
- Net income
- (4)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
Sio Gene Therapies Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$71.6 million | -$32.6 million | 10-K 2022-06-14 · proof | |
| Net income | -$71.9 million | -$32.4 million | 10-Q 2022-08-11 · proof | |
| Cash from operating activities | -$60.3 million | -$46.6 million | 10-K 2022-06-14 · proof | |
| Total assets | $75.1 million | $135.1 million | -44.4% | 10-K 2022-06-14 · proof |
| Total liabilities | $14.7 million | $11.8 million | +25.1% | 10-K 2022-06-14 · proof |
| Cash and cash equivalents | $63.7 million | $119 million | -46.4% | 10-K 2022-06-14 · proof |
- What was Sio Gene Therapies Inc.'s operating income in fiscal 2022?
- Sio Gene Therapies Inc. reported operating income of -$71.6 million for fiscal 2022 (the year ended Mar 31, 2022), against -$32.6 million the year before. Source: the 10-K filed with the SEC on Jun 14, 2022. SEC
- What was Sio Gene Therapies Inc.'s net income in fiscal 2022?
- Sio Gene Therapies Inc. reported net income of -$71.9 million for fiscal 2022 (the year ended Mar 31, 2022), against -$32.4 million the year before. Source: the 10-Q filed with the SEC on Aug 11, 2022 (restated). SEC
- What was Sio Gene Therapies Inc.'s cash from operating activities in fiscal 2022?
- Sio Gene Therapies Inc. reported cash from operating activities of -$60.3 million for fiscal 2022 (the year ended Mar 31, 2022), against -$46.6 million the year before. Source: the 10-K filed with the SEC on Jun 14, 2022. SEC
- What are Sio Gene Therapies Inc.'s total assets?
- As of Mar 31, 2022, Sio Gene Therapies Inc. reported total assets of $75.1 million, against $135.1 million a year earlier (-44.4%). Source: the 10-K filed with the SEC on Jun 14, 2022. SEC
- What are Sio Gene Therapies Inc.'s total liabilities?
- As of Mar 31, 2022, Sio Gene Therapies Inc. reported total liabilities of $14.7 million, against $11.8 million a year earlier (+25.1%). Source: the 10-K filed with the SEC on Jun 14, 2022. SEC
- What are Sio Gene Therapies Inc.'s cash and cash equivalents?
- As of Mar 31, 2022, Sio Gene Therapies Inc. reported cash and cash equivalents of $63.7 million, against $119 million a year earlier (-46.4%). Source: the 10-K filed with the SEC on Jun 14, 2022. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1636050&period_type=annual&limit=5"Information only, not investment advice.